Vancouver’s Lir Life Sciences Corp.is initiating a new phase in its development of alternative obesity treatments, announcing a protocol for an animal study focused on transdermal drug delivery. The research explores a potential needle-free alternative to current GLP-1 and GIP therapies, addressing limitations in cost and accessibility that affect widespread adoption of these medications [[2]]. Obesity affects millions worldwide and is linked to a number of serious health risks,increasing the urgency for more effective and patient-kind treatment options [[1]].
Vancouver-based Lir Life Sciences Corp. has announced the protocol for an animal study evaluating the delivery of obesity therapies using GLP-1 and GIP via a cell-penetrating peptide. The research aims to refine Lir’s transdermal platform, potentially offering a needle-free treatment option for obesity – a significant area of innovation in healthcare technology.
The study, conducted in collaboration with scientific partners, will assess the effectiveness of transdermal administration compared to traditional injections. Participants will receive transdermal formulations followed by an oral glucose tolerance test, with blood glucose monitoring used to evaluate the study’s success.
According to the company, the results will guide future research, helping to identify the most promising drug candidates for further development. “Our goal is to identify the best candidates for transdermal delivery, which will inform our regulatory strategy and potential market authorization applications,” said Edward Mills, CEO of Lir Life Sciences.
